Catherine Smith, MD (@SmithLabSF) header
Catherine Smith, MD (@SmithLabSF) profile picture

Physician scientist. Mom. Advocate for women in science. Working everyday to cure leukemia. Opinions are my own.

San Francisco, CA
Joined May 2019
Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)Photo by Catherine Smith, MD (@SmithLabSF)
Bioinformatics Programmer | University of California San Francisco sjobs.brassring.com/tgwebhos… Come work with us!
385
Replying to @apwiita
Right there with you...
1
My takeaway: worth a try in pts who progress/don't respond to gilteritinib, esp if no RAS/MAPK mutation and esp as bridge to allo.
2
Myelosuppression is a problem but improved with stopping ven and early discontinuation of quizartinib. Note: low dose quizartinib (30mg) was RP2D.
1
CRc rate lower in pts with pre-existing RAS/MAPK mutations (40%) but only 5 pts in this group. Relapse associated w/ emergence of RAS/MAPK mutations, F691L or selection for FLT3 WT clone.
1
Eye-opening response rate of 78% in R/R FLT3-ITD AML, Mostly MLSF/CRi (10/18 responding pts MLSF) but 70% pts with prior gilt treatment and 48% with prior HMA/ven. 34% R/R pts bridged to allo. Better RR frontline (100%) but only 5 pts in this group.
1
OK, I admit it. Having some FOMO with #ASH21 from home. Miss seeing my AML friends and colleagues in person but glad to see @jaltmanmd @Daver_Leukemia among others online this am. Will still try to tweet my favorite #FLT3 talks. First, QUIZ/DAC/Ven in FLT3-ITD AML #leusm
2
1
19
Replying to @MartinTallman
This makes me so sad. He was one of my small group mentors when I did the @ASH_hematology @EHA_Hematology TRTH program in 2010. His encouragement had a huge impact on me. I wouldn't be doing what I am doing now without his mentorship and support. What a loss.
1
2
We're hiring! Come join a great team studying AML and therapeutic resistance (plus we're a lot of fun). Smith Lab - Assistant/Lab Manager in San Francisco, CA for University of California, San Francisco careers.ashg.org/jobs/152018…
2
5
Thanks, Bobby! So much more to come!
3
More single cell sequencing of AML: Treatment resistance-it’s complicated! Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
1
3
12
More single cell sequencing of AML: Treatment resistance-it’s complicated! Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
6
1
21
Proud of this collaboration with Adam Abate’s lab describing genotypic and phenotypic discordance and evolution in AML at the single cell level. Read all about it! @UCSF @UCSFCancer
.@UCSF_BioE @SmithLabSF DAb-seq for simultaneous capture of DNA genotype and cell surface phenotype from single cells at high throughput. go.nature.com/3lig1kg
5
2
11
Really excited about a piece of prelim data today and told family about it over dinner. Daughter: "Are you going to win the Nobel Prize?" Me: "Uh, no." Son: "Will you get in Wikipedia?" Me: "Uh, maybe?" Both: "That's cool." Go back to eating. #WomenInScience #momlife #kids
2
29
I am speechless. The level of racist misogyny in these words is unbelievable. These is no place for this in medicine and medical training. #DNRTulane
2
Replying to @MissionBio
Yay Dalia! I’ve enjoyed working with you #WomenInScience together
A pleasure to see Kevin Shannon give today’s 63rd Annual Faculty Research Lecture in Basic Science. @UCSF @UCSFCancer. Kevin is a model physician scientist, mentor and friend. He’s not on Twitter but he deserves all the #MedTwitter love #leusm #mentor @ASH_hematology
4
12